0
     

Report Added
Report already added
Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027

Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027

The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. Expanding non-oncology applications of epigenetics research is expected to open up new avenues of market expansion. Recent studies on epigenetics have been targeted toward periodontology, focusing on DNA methylation analysis. Increasing advancements in sequencing technology have opened new avenues for epigenetic studies enabling the assessment of specific genes and genome-wide analyses. With technological advancements, epigenetics research is anticipated to provide crucial information for developing dental medicine and expand the scope of ongoing large-scale research projects.

“The kits & reagents segment dominates the epigenetics market through the study period of 2020-2027.”

Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The dominance of kits & reagents segment is attributed to affordable and convenient kits introduced by the market participants. This is expected to suffice the significant elevation in the number of epigenetics research activities conducted in the past few years. Additionally, market players are expanding their product offerings around epigenetics antibodies, which is further expected to supplement the segment’s dominance.

“The histone modifications segment will witness the highest growth in the epigenetics market during the forecast period.”

Based on method, the global epigenetics market is segmented into DNA methylation, histone modifications, and other methods. Histone modifications include different approaches such as, methylation, citrullination, ubiquitination, acetylation, and phosphorylation. Additionally, research professionals are focusing on understanding the potential of histone modifications in oncology which is expected to promote the segment growth through 2022 to 2027.

“North America dominated the epigenetics market in 2021.”

Geographically, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the epigenetics market. North America harbors majority of the key market players leading to maturity of epigenetics market in this region. Also, robust government support for academic & research activities offer opportunity for the key market players to introduce cutting-edge epigenetics products, further intensifying regional market competition.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type - Tier 1: 37%, Tier 2: 23%, and Tier 3: 40%
•By Designation - C-level: 32%, D-level: 26%, and Others: 42%
•By Region - North America: 35%, Europe: 25%, Asia Pacific: 20%, Latin America: 12%, and the Middle East and Africa: 8%

List of Companies Profiled in the Report
•Thermo Fisher Scientific (US)
•Merck KGaA (Germany)
•Illumina, Inc. (US)
•PacBio (US)
•Abcam plc (UK)
•Active Motif, Inc. (US)
•Bio-Rad Laboratories (US)
•Promega Corporation (US)
•PerkinElmer (US)
•Qiagen (Germany)
•New England Biolabs (US)
•Zymo Research Corporation (US)
•Diagenode (Germany)
•F. Hoffmann-La Roche Ltd (Switzerland)
•EpiGentek Group Inc. (US)
•EpiCypher (US)
•Everon Life Sciences (India)
•Fios Genomics (UK)
•GenomeScan (Netherlands)
•Creative Biogene (US)

Research Coverage:
This report provides a detailed picture of the global epigenetics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, method, technique, application, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total epigenetics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
•Market Penetration: Comprehensive information on epigenetics offered by the top 20 players in the epigenetics market. The report analyses the epigenetics market by product & service, method, technique, application, end user, and region.
•Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various epigenetics across key geographic regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
•Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the epigenetics market.
Table of Contents

1INTRODUCTION34
1.1OBJECTIVES OF THE STUDY34
1.2MARKET DEFINITION34
1.2.1INCLUSIONS AND EXCLUSIONS34
1.3MARKET SCOPE35
FIGURE 1EPIGENETICS MARKET35
1.3.1YEARS CONSIDERED FOR THE STUDY36
1.4CURRENCY36
1.5LIMITATIONS36
1.6STAKEHOLDERS37
1.7SUMMARY OF CHANGES37
2RESEARCH METHODOLOGY38
2.1RESEARCH DATA38
FIGURE 2RESEARCH DESIGN38
2.1.1SECONDARY DATA39
2.1.2PRIMARY DATA40
FIGURE 3EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES40
2.2MARKET SIZE ESTIMATION41
FIGURE 4MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EPIGENETICS IN THE MARKET41
FIGURE 5MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 202141
FIGURE 6AVERAGE MARKET SIZE ESTIMATION, 202142
2.3GROWTH RATE ASSUMPTIONS/GROWTH FORECAST43
FIGURE 7EPIGENETICS MARKET: CAGR PROJECTIONS, 2022–202744
FIGURE 8EPIGENETICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES44
FIGURE 9MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH45
2.4MARKET BREAKDOWN AND DATA TRIANGULATION46
FIGURE 10DATA TRIANGULATION METHODOLOGY46
2.5INSIGHTS FROM PRIMARIES47
FIGURE 11MARKET VALIDATION FROM PRIMARY EXPERTS47
2.6RESEARCH ASSUMPTIONS47
2.6.1COVID-19-SPECIFIC ASSUMPTIONS48
2.7RISK ANALYSIS48
3EXECUTIVE SUMMARY49
FIGURE 12EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2027 (USD MILLION)49
FIGURE 13EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)50
FIGURE 14EPIGENETICS MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION)50
FIGURE 15EPIGENETICS MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION)51
FIGURE 16EPIGENETICS MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)51
FIGURE 17GEOGRAPHICAL SNAPSHOT: EPIGENETICS MARKET52
4PREMIUM INSIGHTS53
4.1EPIGENETICS MARKET OVERVIEW53
FIGURE 18GROWING USE OF EPIGENETIC ENZYMES IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH53
4.2NORTH AMERICA: EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2021)54
FIGURE 19KITS & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN EPIGENETICS MARKET IN 202154
4.3NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)55
FIGURE 20DNA METHYLATION TO DOMINATE THE NORTH AMERICAN MARKET TILL 202755
5MARKET OVERVIEW56
5.1INTRODUCTION56
5.2MARKET DYNAMICS56
FIGURE 21EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES56
TABLE 1EPIGENETICS MARKET: IMPACT ANALYSIS57
5.2.1DRIVERS57
5.2.1.1Epigenetic enzymes gaining traction in drug discovery & development57
TABLE 2KEY EPIGENETIC ENZYMES FOR REPURPOSING DRUGS58
5.2.1.2Rising investments, funds, and grants for epigenetics research59
5.2.1.3Declining costs of genome sequencing60
FIGURE 22COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–202060
5.2.2RESTRAINTS60
5.2.2.1Limited applications of epigenomic data in toxicology60
5.2.3OPPORTUNITIES61
5.2.3.1Use of epigenetics in non-oncology applications61
5.2.4CHALLENGES61
5.2.4.1Challenges associated with epigenetic editing61
5.2.4.1.1Off-target effect61
5.2.4.1.2Other challenges62
5.3SCENARIOS ARISING OUT OF UNCERTAINTIES AFFECTING MARKET GROWTH62
FIGURE 23IMPACT OF UNCERTAINTIES ON MARKET GROWTH62
5.4IMPACT OF COVID-19 ON THE EPIGENETICS MARKET63
TABLE 3EPIGENETIC IMPLICATIONS IN CORONAVIRUS INFECTION AND THERAPY63
5.5PORTER’S FIVE FORCES ANALYSIS64
TABLE 4EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS64
5.5.1THREAT OF NEW ENTRANTS64
5.5.2THREAT OF SUBSTITUTES65
5.5.3BARGAINING POWER OF BUYERS65
5.5.4BARGAINING POWER OF SUPPLIERS65
5.5.5DEGREE OF COMPETITION65
5.6ECOSYSTEM ANALYSIS65
FIGURE 24ECOSYSTEM ANALYSIS: EPIGENETICS MARKET66
5.7VALUE CHAIN ANALYSIS66
FIGURE 25VALUE CHAIN ANALYSIS: EPIGENETICS MARKET67
5.8SUPPLY CHAIN ANALYSIS67
TABLE 5SUPPLY CHAIN ECOSYSTEM68
5.9REGULATORY ANALYSIS69
TABLE 6KEY REGULATORY AGENCIES70
6EPIGENETICS MARKET, BY PRODUCT & SERVICE72
6.1INTRODUCTION73
TABLE 7EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)73
6.2KITS & REAGENTS73
TABLE 8EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)74
TABLE 9EPIGENETIC KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION)74
TABLE 10NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)74
TABLE 11EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)75
TABLE 12ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)75
6.2.1ANTIBODIES75
6.2.1.1Increasing demand for recombinant antibodies for the detection of epigenetic targets propels the segment growth75
TABLE 13ANTIBODIES MARKET, BY REGION, 2020–2027 (USD MILLION)76
TABLE 14NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)76
TABLE 15EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)76
TABLE 16ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)77
6.2.2CHIP-SEQUENCING KITS & REAGENTS77
6.2.2.1Versatile applications of ChIP in epigenetic regulatory systems contribute to the segment’s dominant share77
TABLE 17CHIP-SEQ KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION)77
TABLE 18NORTH AMERICA: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 19EUROPE: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)78
TABLE 20ASIA PACIFIC: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)78
6.2.3BISULFITE CONVERSION KITS & REAGENTS79
6.2.3.1Effectiveness of bisulfite conversion in gene-specific and genome-wide analyses to drive the demand for kits & reagents79
TABLE 21BISULFITE CONVERSION KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION)79
TABLE 22NORTH AMERICA: BISULFITE CONVERSION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)79
TABLE 23EUROPE: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 24ASIA PACIFIC: BISULFITE CONVERSION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)80
6.2.4WHOLE-GENOME AMPLIFICATION KITS & REAGENTS80
6.2.4.1Whole-genome amplification maintains the relative proportions of genes present in the original pool, increasing its preference among researchers80
TABLE 25WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)81
TABLE 26NORTH AMERICA: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 27EUROPE: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 28ASIA PACIFIC: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)82
6.2.55-HMC & 5-MC ANALYSIS KITS & REAGENTS82
6.2.5.1Introduction of unique kits drives market growth82
TABLE 295-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION)82
TABLE 30NORTH AMERICA: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 31EUROPE: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 32ASIA PACIFIC: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)83
6.2.6HISTONES84
6.2.6.1Importance of chromatin-associated proteins & histones in epigenetic research to drive the segment growth84
TABLE 33HISTONES MARKET, BY REGION, 2020–2027 (USD MILLION)84
TABLE 34NORTH AMERICA: HISTONES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)84
TABLE 35EUROPE: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 36ASIA PACIFIC: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)85
6.2.7OTHER KITS & REAGENTS85
TABLE 37OTHER KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)85
TABLE 38NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)86
TABLE 39EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)86
TABLE 40ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)86
6.3ENZYMES87
TABLE 41EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)87
TABLE 42EPIGENETIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)87
TABLE 43NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)88
TABLE 44EUROPE: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)88
TABLE 45ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)88
6.3.1DNA-MODIFYING ENZYMES89
6.3.1.1Growing applications of DNA methylation to contribute to the segment’s dominant share89
TABLE 46DNA-MODIFYING ENZYMES MARKET, BY REGION,
2020–2027 (USD MILLION)89
TABLE 47NORTH AMERICA: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)89
TABLE 48EUROPE: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)90
TABLE 49ASIA PACIFIC: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)90
6.3.2PROTEIN-MODIFYING ENZYMES90
6.3.2.1Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive the segment growth90
TABLE 50PROTEIN-MODIFYING ENZYMES MARKET, BY REGION,
2020–2027 (USD MILLION)91
TABLE 51NORTH AMERICA: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 52EUROPE: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)91
TABLE 53ASIA PACIFIC: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)92
6.3.3OTHER ENZYMES92
TABLE 54OTHER ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)92
TABLE 55NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)93
TABLE 56EUROPE: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)93
TABLE 57ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)93
6.4INSTRUMENTS & ACCESSORIES94
6.4.1WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO CONTRIBUTE TO THE SEGMENT REVENUE94
TABLE 58EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY REGION,
2020–2027 (USD MILLION)94
TABLE 59NORTH AMERICA: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)94
TABLE 60EUROPE: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 61ASIA PACIFIC: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)95
6.5SOFTWARE95
6.5.1DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION, CHROMATIN, AND RNA ANALYSIS TO PROPEL SEGMENT GROWTH95
TABLE 62EPIGENETIC SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)96
TABLE 63NORTH AMERICA: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION)96
TABLE 64EUROPE: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION)96
TABLE 65ASIA PACIFIC: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION)97
6.6SERVICES97
6.6.1EXPANDING POOL OF PROVIDERS TO DRIVE THE SERVICES SEGMENT97
TABLE 66EPIGENETIC SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)98
TABLE 67NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)98
TABLE 68EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)98
TABLE 69ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)99
7EPIGENETICS MARKET, BY METHOD100
7.1INTRODUCTION101
TABLE 70EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)101
7.2DNA METHYLATION101
7.2.1DNA METHYLATION TO DOMINATE THE METHODS MARKET TILL 2027101
TABLE 71EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,
2020–2027 (USD MILLION)102
TABLE 72NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION,
BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 73EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 74ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION)103
7.3HISTONE MODIFICATIONS103
7.3.1TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENT GROWTH103
TABLE 75COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS103
TABLE 76EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION,
2020–2027 (USD MILLION)104
TABLE 77NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)104
TABLE 78EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 79ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)105
7.4OTHER METHODS105
TABLE 80EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,
2020–2027 (USD MILLION)106
TABLE 81NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS,
BY COUNTRY, 2020–2027 (USD MILLION)106
TABLE 82EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,
2020–2027 (USD MILLION)106
TABLE 83ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027 (USD MILLION)107
8EPIGENETICS MARKET, BY TECHNIQUE108
8.1INTRODUCTION109
TABLE 84EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)109
8.2NGS109
8.2.1NGS OFFERS COMPREHENSIVE EPIGENETIC PROFILES,
WHICH DRIVES ADOPTION109
TABLE 85EPIGENETICS MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)110
TABLE 86NORTH AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION)110
TABLE 87EUROPE: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION)110
TABLE 88ASIA PACIFIC: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION)111
8.3PCR & QPCR111
8.3.1RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO PROPEL THE SEGMENT GROWTH111
TABLE 89EPIGENETICS MARKET FOR PCR & QPCR, BY REGION,
2020–2027 (USD MILLION)112
TABLE 90NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 91EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2020–2027 (USD MILLION)112
TABLE 92ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2020–2027 (USD MILLION)113
8.4MASS SPECTROMETRY113
8.4.1GROWING DEMAND FOR MASS SPECTROMETRY IN HISTONE EPIGENETICS STUDIES TO DRIVE THE SEGMENT GROWTH113
TABLE 93EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION,
2020–2027 (USD MILLION)113
TABLE 94NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2020–2027 (USD MILLION)114
TABLE 95EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027 (USD MILLION)114
TABLE 96ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2020–2027 (USD MILLION)114
8.5SONICATION115
8.5.1ADVENT OF IMPROVED HIGH-THROUGHPUT SONICATION TO PROPEL ITS ADOPTION IN EPIGENETICS STUDIES115
TABLE 97EPIGENETICS MARKET FOR SONICATION, BY REGION,
2020–2027 (USD MILLION)115
TABLE 98NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2020–2027 (USD MILLION)115
TABLE 99EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2020–2027 (USD MILLION)116
TABLE 100ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2020–2027 (USD MILLION)116
8.6OTHER TECHNIQUES116
TABLE 101EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION,
2020–2027 (USD MILLION)117
TABLE 102NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES,
BY COUNTRY, 2020–2027 (USD MILLION)117
TABLE 103EUROPE: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION)117
TABLE 104ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION)118
9EPIGENETICS MARKET, BY APPLICATION119
9.1INTRODUCTION120
TABLE 105EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)120
9.2ONCOLOGY120
9.2.1ONCOLOGY TO HOLD LARGEST SHARE OF THE APPLICATIONS
SEGMENT TILL 2027120
TABLE 106EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS121
TABLE 107EPIGENETICS MARKET FOR ONCOLOGY, BY REGION,
2020–2027 (USD MILLION)123
TABLE 108NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)123
TABLE 109EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION)123
TABLE 110ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION)124
9.3METABOLIC DISEASES124
9.3.1EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT
TO DRIVE THE SEGMENT GROWTH124
TABLE 111EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION,
2020–2027 (USD MILLION)125
TABLE 112NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)125
TABLE 113EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)125
TABLE 114ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)126
9.4IMMUNOLOGY126
9.4.1RISING DEMAND FOR EPIGENETICS PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE SEGMENT’S GROWTH126
TABLE 115EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,
2020–2027 (USD MILLION)126
TABLE 116NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)127
TABLE 117EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2020–2027 (USD MILLION)127
TABLE 118ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)127
9.5DEVELOPMENTAL BIOLOGY128
9.5.1GROWING R&D IN DEVELOPMENTAL BIOLOGY TO PROPEL THE SEGMENT’S GROWTH128
TABLE 119EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,
2020–2027 (USD MILLION)128
TABLE 120NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION)128
TABLE 121EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION)129
TABLE 122ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION)129
9.6CARDIOVASCULAR DISEASES129
9.6.1EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING THE ETIOLOGY OF CARDIOVASCULAR DISEASES TO PROPEL PRODUCT ADOPTION129
TABLE 123EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)130
TABLE 124NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)130
TABLE 125EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)130
TABLE 126ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)131
9.7OTHER APPLICATIONS131
TABLE 127EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION,
2020–2027 (USD MILLION)131
TABLE 128NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)132
TABLE 129EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)132
TABLE 130ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)132

10EPIGENETICS MARKET, BY END USER133
10.1INTRODUCTION134
TABLE 131EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)134
10.2ACADEMIC & RESEARCH INSTITUTES134
10.2.1HIGH SHARE ATTRIBUTED TO RISING COLLABORATIONS AMONG RESEARCH INSTITUTES AND DEMAND FOR CANCER EPIGENETICS134
TABLE 132EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)135
TABLE 133NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)135
TABLE 134EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)135
TABLE 135ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)136
10.3PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES136
10.3.1HIGH NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE THE SEGMENT GROWTH136
TABLE 136EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)137
TABLE 137NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)137
TABLE 138EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)137
TABLE 139ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)138
10.4HOSPITALS & CLINICS138
10.4.1RISING IMPORTANCE OF DNA METHYLATION MEASUREMENTS TO DRIVE SEGMENT GROWTH138
TABLE 140EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION,
2020–2027 (USD MILLION)139
TABLE 141NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2020–2027 (USD MILLION)139
TABLE 142EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)139
TABLE 143ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2020–2027 (USD MILLION)140
11EPIGENETICS MARKET, BY REGION141
11.1INTRODUCTION142
TABLE 144EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION)142
11.2NORTH AMERICA142
FIGURE 26NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT143
TABLE 145NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)143
TABLE 146NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)144
TABLE 147NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)144
TABLE 148NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)145
TABLE 149NORTH AMERICA: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION)145
TABLE 150NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)145
TABLE 151NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)146
TABLE 152NORTH AMERICA: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)146
11.2.1US146
11.2.1.1A strong network of well-established epigenetic product manufacturers is the key growth contributor146
TABLE 153US: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)147
TABLE 154US: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)147
TABLE 155US: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)148
TABLE 156US: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)148
TABLE 157US: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)148
TABLE 158US: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)149
TABLE 159US: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)149
11.2.2CANADA149
11.2.2.1Government initiatives to boost epigenetics research contribute to the market growth149
TABLE 160CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)150
TABLE 161CANADA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)150
TABLE 162CANADA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)151
TABLE 163CANADA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)151
TABLE 164CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)151
TABLE 165CANADA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)152
TABLE 166CANADA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)152
11.3EUROPE152
TABLE 167EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)153
TABLE 168EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)153
TABLE 169EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)153
TABLE 170EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)154
TABLE 171EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)154
TABLE 172EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)154
TABLE 173EUROPE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)155
TABLE 174EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)155
11.3.1GERMANY155
11.3.1.1Significant investments in the NGS market space in Germany expected to boost the uptake of epigenetics products155
TABLE 175GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)156
TABLE 176GERMANY: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)156
TABLE 177GERMANY: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)156
TABLE 178GERMANY: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)157
TABLE 179GERMANY: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)157
TABLE 180GERMANY: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)157
TABLE 181GERMANY: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)158
11.3.2UK158
11.3.2.1Rising acceptance of genome-based diagnostic techniques to drive the UK epigenetics market158
TABLE 182UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)158
TABLE 183UK: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)159
TABLE 184UK: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)159
TABLE 185UK: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)159
TABLE 186UK: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)160
TABLE 187UK: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)160
TABLE 188UK: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)160
11.3.3FRANCE161
11.3.3.1Growing demand for PCR technologies propelled by favorable government initiatives to boost the market growth161
TABLE 189FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)161
TABLE 190FRANCE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)161
TABLE 191FRANCE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)162
TABLE 192FRANCE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)162
TABLE 193FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)162
TABLE 194FRANCE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)163
TABLE 195FRANCE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)163
11.3.4REST OF EUROPE163
TABLE 196REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)164
TABLE 197REST OF EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)164
TABLE 198REST OF EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)165
TABLE 199REST OF EUROPE: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION)165
TABLE 200REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)165
TABLE 201REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)166
TABLE 202REST OF EUROPE: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)166
11.4ASIA PACIFIC167
FIGURE 27ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT167
TABLE 203ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)168
TABLE 204ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)168
TABLE 205ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)169
TABLE 206ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)169
TABLE 207ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION)169
TABLE 208ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)170
TABLE 209ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)170
TABLE 210ASIA PACIFIC: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)170
11.4.1JAPAN171
11.4.1.1Research-academia collaborations have driven awareness of epigenetics in the country171
TABLE 211JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)171
TABLE 212JAPAN: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)172
TABLE 213JAPAN: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)172
TABLE 214JAPAN: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)172
TABLE 215JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)173
TABLE 216JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)173
TABLE 217JAPAN: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)173
11.4.2CHINA174
11.4.2.1Increasing research on genomics and high demand for personalized medicine to propel the Chinese market174
TABLE 218CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)174
TABLE 219CHINA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)175
TABLE 220CHINA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)175
TABLE 221CHINA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)175
TABLE 222CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)176
TABLE 223CHINA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)176
TABLE 224CHINA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)176
11.4.3INDIA177
11.4.3.1Activities to strengthen genomics research by expanding the base of biotechnology facilities to drive market growth177
TABLE 225INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)177
TABLE 226INDIA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)178
TABLE 227INDIA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)178
TABLE 228INDIA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)178
TABLE 229INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)179
TABLE 230INDIA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)179
TABLE 231INDIA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)179
11.4.4REST OF ASIA PACIFIC180
TABLE 232REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)180
TABLE 233REST OF ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)180
TABLE 234REST OF ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)181
TABLE 235REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION)181
TABLE 236REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)181
TABLE 237REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)182
TABLE 238REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)182
11.5LATIN AMERICA182
11.5.1ADVANCEMENTS IN EPIGENETIC ANALYSIS AND CHARACTERIZATION TO BOOST THE UPTAKE OF MARKET PRODUCTS182
TABLE 239LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)183
TABLE 240LATIN AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)183
TABLE 241LATIN AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION)184
TABLE 242LATIN AMERICA: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION)184
TABLE 243LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION)184
TABLE 244LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)185
TABLE 245LATIN AMERICA: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION)185
11.6MIDDLE EAST & AFRICA185
11.6.1RISING FUNDING AND PARTNERSHIPS IN RESEARCH TO BOOST MARKET GROWTH IN THE MIDDLE EAST & AFRICA185
TABLE 246MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)186
TABLE 247MIDDLE EAST & AFRICA: EPIGENETIC KITS & REAGENTS MARKET, BY TY

Report Title: Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline